nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—L-DOPA—Melphalan—hematologic cancer	0.426	1	CrCrCtD
Methyldopa—L-DOPA—PSIP1—hematologic cancer	0.00314	0.324	CrCbGaD
Methyldopa—COMT—hematopoietic system—hematologic cancer	0.00217	0.112	CbGeAlD
Methyldopa—Isoprenaline—PIK3R1—hematologic cancer	0.00195	0.201	CrCbGaD
Methyldopa—DDC—lung—hematologic cancer	0.00191	0.0986	CbGeAlD
Methyldopa—DDC—testis—hematologic cancer	0.0018	0.093	CbGeAlD
Methyldopa—COMT—gonad—hematologic cancer	0.00165	0.0854	CbGeAlD
Methyldopa—COMT—blood—hematologic cancer	0.00144	0.0744	CbGeAlD
Methyldopa—COMT—bone marrow—hematologic cancer	0.00139	0.072	CbGeAlD
Methyldopa—DDC—lymph node—hematologic cancer	0.0013	0.0674	CbGeAlD
Methyldopa—COMT—lung—hematologic cancer	0.00126	0.0652	CbGeAlD
Methyldopa—COMT—testis—hematologic cancer	0.00119	0.0615	CbGeAlD
Methyldopa—ADRA2A—hematopoietic system—hematologic cancer	0.00111	0.0572	CbGeAlD
Methyldopa—Aminosalicylic Acid—ALOX5—hematologic cancer	0.0011	0.114	CrCbGaD
Methyldopa—Mesalazine—ALOX5—hematologic cancer	0.000866	0.0895	CrCbGaD
Methyldopa—COMT—lymph node—hematologic cancer	0.000862	0.0446	CbGeAlD
Methyldopa—ADRA2A—gonad—hematologic cancer	0.00084	0.0435	CbGeAlD
Methyldopa—ADRA2A—blood—hematologic cancer	0.000732	0.0379	CbGeAlD
Methyldopa—Aminosalicylic Acid—MPO—hematologic cancer	0.000712	0.0735	CrCbGaD
Methyldopa—ADRA2A—lung—hematologic cancer	0.000642	0.0332	CbGeAlD
Methyldopa—ADRA2A—testis—hematologic cancer	0.000606	0.0313	CbGeAlD
Methyldopa—Mesalazine—MPO—hematologic cancer	0.000558	0.0577	CrCbGaD
Methyldopa—ADRA2A—lymph node—hematologic cancer	0.000439	0.0227	CbGeAlD
Methyldopa—Norepinephrine—SLC22A1—hematologic cancer	0.000388	0.0401	CrCbGaD
Methyldopa—Dopamine—SLC22A1—hematologic cancer	0.000361	0.0373	CrCbGaD
Methyldopa—Epinephrine—SLC22A1—hematologic cancer	0.000352	0.0364	CrCbGaD
Methyldopa—Epinephrine—TNF—hematologic cancer	0.000254	0.0262	CrCbGaD
Methyldopa—Infestation NOS—Epirubicin—hematologic cancer	0.000102	0.000237	CcSEcCtD
Methyldopa—Infestation—Epirubicin—hematologic cancer	0.000102	0.000237	CcSEcCtD
Methyldopa—Rash—Thiotepa—hematologic cancer	0.000101	0.000237	CcSEcCtD
Methyldopa—Dermatitis—Thiotepa—hematologic cancer	0.000101	0.000237	CcSEcCtD
Methyldopa—Diarrhoea—Alitretinoin—hematologic cancer	0.000101	0.000236	CcSEcCtD
Methyldopa—Agranulocytosis—Methotrexate—hematologic cancer	0.000101	0.000236	CcSEcCtD
Methyldopa—Headache—Thiotepa—hematologic cancer	0.000101	0.000235	CcSEcCtD
Methyldopa—Diarrhoea—Ifosfamide—hematologic cancer	0.0001	0.000234	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—hematologic cancer	0.0001	0.000234	CcSEcCtD
Methyldopa—Nausea—Vinorelbine—hematologic cancer	0.0001	0.000234	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—hematologic cancer	9.97e-05	0.000233	CcSEcCtD
Methyldopa—Body temperature increased—Cisplatin—hematologic cancer	9.97e-05	0.000233	CcSEcCtD
Methyldopa—Asthenia—Irinotecan—hematologic cancer	9.97e-05	0.000233	CcSEcCtD
Methyldopa—Asthenia—Mitoxantrone—hematologic cancer	9.97e-05	0.000233	CcSEcCtD
Methyldopa—Myalgia—Betamethasone—hematologic cancer	9.92e-05	0.000232	CcSEcCtD
Methyldopa—Myalgia—Dexamethasone—hematologic cancer	9.92e-05	0.000232	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—hematologic cancer	9.9e-05	0.000231	CcSEcCtD
Methyldopa—Vomiting—Thalidomide—hematologic cancer	9.89e-05	0.000231	CcSEcCtD
Methyldopa—Dizziness—Carmustine—hematologic cancer	9.88e-05	0.000231	CcSEcCtD
Methyldopa—Constipation—Etoposide—hematologic cancer	9.88e-05	0.000231	CcSEcCtD
Methyldopa—Rash—Thalidomide—hematologic cancer	9.81e-05	0.000229	CcSEcCtD
Methyldopa—Dermatitis—Thalidomide—hematologic cancer	9.8e-05	0.000229	CcSEcCtD
Methyldopa—Dizziness—Alitretinoin—hematologic cancer	9.79e-05	0.000229	CcSEcCtD
Methyldopa—Diarrhoea—Vincristine—hematologic cancer	9.76e-05	0.000228	CcSEcCtD
Methyldopa—Headache—Thalidomide—hematologic cancer	9.75e-05	0.000228	CcSEcCtD
Methyldopa—Hepatitis—Methotrexate—hematologic cancer	9.74e-05	0.000227	CcSEcCtD
Methyldopa—Asthenia—Gemcitabine—hematologic cancer	9.71e-05	0.000227	CcSEcCtD
Methyldopa—Dizziness—Ifosfamide—hematologic cancer	9.67e-05	0.000226	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—hematologic cancer	9.6e-05	0.000224	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—hematologic cancer	9.59e-05	0.000224	CcSEcCtD
Methyldopa—Nausea—Thiotepa—hematologic cancer	9.55e-05	0.000223	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	9.55e-05	0.000223	CcSEcCtD
Methyldopa—Oedema—Dexamethasone—hematologic cancer	9.51e-05	0.000222	CcSEcCtD
Methyldopa—Oedema—Betamethasone—hematologic cancer	9.51e-05	0.000222	CcSEcCtD
Methyldopa—Diarrhoea—Irinotecan—hematologic cancer	9.5e-05	0.000222	CcSEcCtD
Methyldopa—Diarrhoea—Mitoxantrone—hematologic cancer	9.5e-05	0.000222	CcSEcCtD
Methyldopa—Vomiting—Carmustine—hematologic cancer	9.5e-05	0.000222	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—hematologic cancer	9.48e-05	0.000221	CcSEcCtD
Methyldopa—Infection—Dexamethasone—hematologic cancer	9.45e-05	0.000221	CcSEcCtD
Methyldopa—Infection—Betamethasone—hematologic cancer	9.45e-05	0.000221	CcSEcCtD
Methyldopa—Dizziness—Vincristine—hematologic cancer	9.43e-05	0.00022	CcSEcCtD
Methyldopa—Rash—Carmustine—hematologic cancer	9.42e-05	0.00022	CcSEcCtD
Methyldopa—Dermatitis—Carmustine—hematologic cancer	9.41e-05	0.00022	CcSEcCtD
Methyldopa—Vomiting—Alitretinoin—hematologic cancer	9.41e-05	0.00022	CcSEcCtD
Methyldopa—Paraesthesia—Triamcinolone—hematologic cancer	9.41e-05	0.00022	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—hematologic cancer	9.4e-05	0.000219	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—hematologic cancer	9.4e-05	0.000219	CcSEcCtD
Methyldopa—Headache—Carmustine—hematologic cancer	9.36e-05	0.000219	CcSEcCtD
Methyldopa—Rash—Alitretinoin—hematologic cancer	9.33e-05	0.000218	CcSEcCtD
Methyldopa—Nervous system disorder—Dexamethasone—hematologic cancer	9.32e-05	0.000218	CcSEcCtD
Methyldopa—Nervous system disorder—Betamethasone—hematologic cancer	9.32e-05	0.000218	CcSEcCtD
Methyldopa—Dermatitis—Alitretinoin—hematologic cancer	9.32e-05	0.000218	CcSEcCtD
Methyldopa—Thrombocytopenia—Dexamethasone—hematologic cancer	9.31e-05	0.000217	CcSEcCtD
Methyldopa—Thrombocytopenia—Betamethasone—hematologic cancer	9.31e-05	0.000217	CcSEcCtD
Methyldopa—Vomiting—Ifosfamide—hematologic cancer	9.3e-05	0.000217	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—hematologic cancer	9.29e-05	0.000217	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—hematologic cancer	9.28e-05	0.000217	CcSEcCtD
Methyldopa—Headache—Alitretinoin—hematologic cancer	9.27e-05	0.000217	CcSEcCtD
Methyldopa—Diarrhoea—Gemcitabine—hematologic cancer	9.26e-05	0.000216	CcSEcCtD
Methyldopa—Nausea—Thalidomide—hematologic cancer	9.24e-05	0.000216	CcSEcCtD
Methyldopa—Rash—Ifosfamide—hematologic cancer	9.22e-05	0.000215	CcSEcCtD
Methyldopa—Dermatitis—Ifosfamide—hematologic cancer	9.21e-05	0.000215	CcSEcCtD
Methyldopa—Dizziness—Irinotecan—hematologic cancer	9.18e-05	0.000214	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—hematologic cancer	9.16e-05	0.000214	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—hematologic cancer	9.13e-05	0.000213	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—hematologic cancer	9.12e-05	0.000213	CcSEcCtD
Methyldopa—Vomiting—Vincristine—hematologic cancer	9.07e-05	0.000212	CcSEcCtD
Methyldopa—Asthenia—Cisplatin—hematologic cancer	9.05e-05	0.000211	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—hematologic cancer	9.04e-05	0.000211	CcSEcCtD
Methyldopa—Rash—Vincristine—hematologic cancer	8.99e-05	0.00021	CcSEcCtD
Methyldopa—Dermatitis—Vincristine—hematologic cancer	8.98e-05	0.00021	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—hematologic cancer	8.96e-05	0.000209	CcSEcCtD
Methyldopa—Headache—Vincristine—hematologic cancer	8.93e-05	0.000209	CcSEcCtD
Methyldopa—Hepatobiliary disease—Doxorubicin—hematologic cancer	8.89e-05	0.000208	CcSEcCtD
Methyldopa—Nausea—Carmustine—hematologic cancer	8.87e-05	0.000207	CcSEcCtD
Methyldopa—Angiopathy—Methotrexate—hematologic cancer	8.84e-05	0.000206	CcSEcCtD
Methyldopa—Vomiting—Mitoxantrone—hematologic cancer	8.83e-05	0.000206	CcSEcCtD
Methyldopa—Vomiting—Irinotecan—hematologic cancer	8.83e-05	0.000206	CcSEcCtD
Methyldopa—Nausea—Alitretinoin—hematologic cancer	8.79e-05	0.000205	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—hematologic cancer	8.78e-05	0.000205	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—hematologic cancer	8.77e-05	0.000205	CcSEcCtD
Methyldopa—Rash—Irinotecan—hematologic cancer	8.76e-05	0.000205	CcSEcCtD
Methyldopa—Rash—Mitoxantrone—hematologic cancer	8.76e-05	0.000205	CcSEcCtD
Methyldopa—Dermatitis—Irinotecan—hematologic cancer	8.75e-05	0.000204	CcSEcCtD
Methyldopa—Dermatitis—Mitoxantrone—hematologic cancer	8.75e-05	0.000204	CcSEcCtD
Methyldopa—Headache—Irinotecan—hematologic cancer	8.7e-05	0.000203	CcSEcCtD
Methyldopa—Headache—Mitoxantrone—hematologic cancer	8.7e-05	0.000203	CcSEcCtD
Methyldopa—Nausea—Ifosfamide—hematologic cancer	8.69e-05	0.000203	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Betamethasone—hematologic cancer	8.66e-05	0.000202	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	8.66e-05	0.000202	CcSEcCtD
Methyldopa—Arthralgia—Prednisone—hematologic cancer	8.64e-05	0.000202	CcSEcCtD
Methyldopa—Myalgia—Prednisone—hematologic cancer	8.64e-05	0.000202	CcSEcCtD
Methyldopa—Diarrhoea—Cisplatin—hematologic cancer	8.63e-05	0.000202	CcSEcCtD
Methyldopa—Vomiting—Gemcitabine—hematologic cancer	8.6e-05	0.000201	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—hematologic cancer	8.59e-05	0.000201	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	8.58e-05	0.0002	CcSEcCtD
Methyldopa—Paraesthesia—Betamethasone—hematologic cancer	8.54e-05	0.000199	CcSEcCtD
Methyldopa—Paraesthesia—Dexamethasone—hematologic cancer	8.54e-05	0.000199	CcSEcCtD
Methyldopa—Mental disorder—Methotrexate—hematologic cancer	8.53e-05	0.000199	CcSEcCtD
Methyldopa—Rash—Gemcitabine—hematologic cancer	8.53e-05	0.000199	CcSEcCtD
Methyldopa—Dermatitis—Gemcitabine—hematologic cancer	8.52e-05	0.000199	CcSEcCtD
Methyldopa—Hypersensitivity—Etoposide—hematologic cancer	8.51e-05	0.000199	CcSEcCtD
Methyldopa—Headache—Gemcitabine—hematologic cancer	8.48e-05	0.000198	CcSEcCtD
Methyldopa—Nausea—Vincristine—hematologic cancer	8.47e-05	0.000198	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—hematologic cancer	8.46e-05	0.000198	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—hematologic cancer	8.43e-05	0.000197	CcSEcCtD
Methyldopa—Hypersensitivity—Prednisolone—hematologic cancer	8.4e-05	0.000196	CcSEcCtD
Methyldopa—Asthenia—Etoposide—hematologic cancer	8.29e-05	0.000194	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—hematologic cancer	8.29e-05	0.000194	CcSEcCtD
Methyldopa—Body temperature increased—Triamcinolone—hematologic cancer	8.28e-05	0.000193	CcSEcCtD
Methyldopa—Oedema—Prednisone—hematologic cancer	8.28e-05	0.000193	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—hematologic cancer	8.27e-05	0.000193	CcSEcCtD
Methyldopa—Nausea—Irinotecan—hematologic cancer	8.25e-05	0.000193	CcSEcCtD
Methyldopa—Nausea—Mitoxantrone—hematologic cancer	8.25e-05	0.000193	CcSEcCtD
Methyldopa—Infection—Prednisone—hematologic cancer	8.23e-05	0.000192	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—hematologic cancer	8.22e-05	0.000192	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Betamethasone—hematologic cancer	8.21e-05	0.000192	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Dexamethasone—hematologic cancer	8.21e-05	0.000192	CcSEcCtD
Methyldopa—Nervous system disorder—Prednisone—hematologic cancer	8.12e-05	0.00019	CcSEcCtD
Methyldopa—Skin disorder—Prednisone—hematologic cancer	8.04e-05	0.000188	CcSEcCtD
Methyldopa—Nausea—Gemcitabine—hematologic cancer	8.04e-05	0.000188	CcSEcCtD
Methyldopa—Vomiting—Cisplatin—hematologic cancer	8.02e-05	0.000187	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—hematologic cancer	7.99e-05	0.000187	CcSEcCtD
Methyldopa—Rash—Cisplatin—hematologic cancer	7.95e-05	0.000186	CcSEcCtD
Methyldopa—Dermatitis—Cisplatin—hematologic cancer	7.94e-05	0.000186	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—hematologic cancer	7.9e-05	0.000185	CcSEcCtD
Methyldopa—Cardiac disorder—Doxorubicin—hematologic cancer	7.83e-05	0.000183	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—hematologic cancer	7.82e-05	0.000183	CcSEcCtD
Methyldopa—Hypersensitivity—Triamcinolone—hematologic cancer	7.72e-05	0.00018	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—hematologic cancer	7.65e-05	0.000179	CcSEcCtD
Methyldopa—Dizziness—Etoposide—hematologic cancer	7.64e-05	0.000178	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—hematologic cancer	7.6e-05	0.000178	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—hematologic cancer	7.59e-05	0.000177	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Prednisone—hematologic cancer	7.54e-05	0.000176	CcSEcCtD
Methyldopa—Dizziness—Prednisolone—hematologic cancer	7.54e-05	0.000176	CcSEcCtD
Methyldopa—Asthenia—Triamcinolone—hematologic cancer	7.52e-05	0.000176	CcSEcCtD
Methyldopa—Body temperature increased—Betamethasone—hematologic cancer	7.52e-05	0.000176	CcSEcCtD
Methyldopa—Body temperature increased—Dexamethasone—hematologic cancer	7.52e-05	0.000176	CcSEcCtD
Methyldopa—Nausea—Cisplatin—hematologic cancer	7.49e-05	0.000175	CcSEcCtD
Methyldopa—Paraesthesia—Prednisone—hematologic cancer	7.44e-05	0.000174	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—hematologic cancer	7.39e-05	0.000173	CcSEcCtD
Methyldopa—Vomiting—Etoposide—hematologic cancer	7.35e-05	0.000172	CcSEcCtD
Methyldopa—Rash—Etoposide—hematologic cancer	7.28e-05	0.00017	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—hematologic cancer	7.28e-05	0.00017	CcSEcCtD
Methyldopa—Headache—Etoposide—hematologic cancer	7.24e-05	0.000169	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—hematologic cancer	7.24e-05	0.000169	CcSEcCtD
Methyldopa—Arthralgia—Methotrexate—hematologic cancer	7.22e-05	0.000169	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—hematologic cancer	7.22e-05	0.000169	CcSEcCtD
Methyldopa—Rash—Prednisolone—hematologic cancer	7.18e-05	0.000168	CcSEcCtD
Methyldopa—Dermatitis—Prednisolone—hematologic cancer	7.18e-05	0.000168	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	7.17e-05	0.000167	CcSEcCtD
Methyldopa—Headache—Prednisolone—hematologic cancer	7.14e-05	0.000167	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—hematologic cancer	7.1e-05	0.000166	CcSEcCtD
Methyldopa—Constipation—Prednisone—hematologic cancer	7.08e-05	0.000165	CcSEcCtD
Methyldopa—Dizziness—Triamcinolone—hematologic cancer	6.93e-05	0.000162	CcSEcCtD
Methyldopa—Infection—Methotrexate—hematologic cancer	6.88e-05	0.000161	CcSEcCtD
Methyldopa—Nausea—Etoposide—hematologic cancer	6.86e-05	0.00016	CcSEcCtD
Methyldopa—Asthenia—Betamethasone—hematologic cancer	6.82e-05	0.000159	CcSEcCtD
Methyldopa—Asthenia—Dexamethasone—hematologic cancer	6.82e-05	0.000159	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—hematologic cancer	6.79e-05	0.000158	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—hematologic cancer	6.78e-05	0.000158	CcSEcCtD
Methyldopa—Nausea—Prednisolone—hematologic cancer	6.77e-05	0.000158	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—hematologic cancer	6.76e-05	0.000158	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—hematologic cancer	6.76e-05	0.000158	CcSEcCtD
Methyldopa—Skin disorder—Methotrexate—hematologic cancer	6.72e-05	0.000157	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.71e-05	0.000157	CcSEcCtD
Methyldopa—Vomiting—Triamcinolone—hematologic cancer	6.66e-05	0.000156	CcSEcCtD
Methyldopa—Rash—Triamcinolone—hematologic cancer	6.61e-05	0.000154	CcSEcCtD
Methyldopa—Dermatitis—Triamcinolone—hematologic cancer	6.6e-05	0.000154	CcSEcCtD
Methyldopa—Leukopenia—Doxorubicin—hematologic cancer	6.57e-05	0.000153	CcSEcCtD
Methyldopa—Headache—Triamcinolone—hematologic cancer	6.56e-05	0.000153	CcSEcCtD
Methyldopa—Body temperature increased—Prednisone—hematologic cancer	6.55e-05	0.000153	CcSEcCtD
Methyldopa—Diarrhoea—Dexamethasone—hematologic cancer	6.51e-05	0.000152	CcSEcCtD
Methyldopa—Diarrhoea—Betamethasone—hematologic cancer	6.51e-05	0.000152	CcSEcCtD
Methyldopa—Oedema—Epirubicin—hematologic cancer	6.48e-05	0.000151	CcSEcCtD
Methyldopa—Infection—Epirubicin—hematologic cancer	6.43e-05	0.00015	CcSEcCtD
Methyldopa—Nervous system disorder—Epirubicin—hematologic cancer	6.35e-05	0.000148	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—hematologic cancer	6.34e-05	0.000148	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.3e-05	0.000147	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—hematologic cancer	6.29e-05	0.000147	CcSEcCtD
Methyldopa—Dizziness—Dexamethasone—hematologic cancer	6.29e-05	0.000147	CcSEcCtD
Methyldopa—Dizziness—Betamethasone—hematologic cancer	6.29e-05	0.000147	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—hematologic cancer	6.25e-05	0.000146	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—hematologic cancer	6.25e-05	0.000146	CcSEcCtD
Methyldopa—Nausea—Triamcinolone—hematologic cancer	6.22e-05	0.000145	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—hematologic cancer	6.21e-05	0.000145	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	6.21e-05	0.000145	CcSEcCtD
Methyldopa—Hypersensitivity—Prednisone—hematologic cancer	6.1e-05	0.000142	CcSEcCtD
Methyldopa—Vomiting—Dexamethasone—hematologic cancer	6.05e-05	0.000141	CcSEcCtD
Methyldopa—Vomiting—Betamethasone—hematologic cancer	6.05e-05	0.000141	CcSEcCtD
Methyldopa—Rash—Betamethasone—hematologic cancer	6e-05	0.00014	CcSEcCtD
Methyldopa—Rash—Dexamethasone—hematologic cancer	6e-05	0.00014	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—hematologic cancer	5.99e-05	0.00014	CcSEcCtD
Methyldopa—Dermatitis—Dexamethasone—hematologic cancer	5.99e-05	0.00014	CcSEcCtD
Methyldopa—Dermatitis—Betamethasone—hematologic cancer	5.99e-05	0.00014	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.97e-05	0.00014	CcSEcCtD
Methyldopa—Headache—Betamethasone—hematologic cancer	5.96e-05	0.000139	CcSEcCtD
Methyldopa—Headache—Dexamethasone—hematologic cancer	5.96e-05	0.000139	CcSEcCtD
Methyldopa—Infection—Doxorubicin—hematologic cancer	5.95e-05	0.000139	CcSEcCtD
Methyldopa—Asthenia—Prednisone—hematologic cancer	5.94e-05	0.000139	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.9e-05	0.000138	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—hematologic cancer	5.88e-05	0.000137	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—hematologic cancer	5.87e-05	0.000137	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—hematologic cancer	5.82e-05	0.000136	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—hematologic cancer	5.82e-05	0.000136	CcSEcCtD
Methyldopa—Diarrhoea—Prednisone—hematologic cancer	5.67e-05	0.000132	CcSEcCtD
Methyldopa—Nausea—Betamethasone—hematologic cancer	5.65e-05	0.000132	CcSEcCtD
Methyldopa—Nausea—Dexamethasone—hematologic cancer	5.65e-05	0.000132	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.59e-05	0.000131	CcSEcCtD
Methyldopa—Constipation—Epirubicin—hematologic cancer	5.54e-05	0.000129	CcSEcCtD
Methyldopa—Dizziness—Prednisone—hematologic cancer	5.48e-05	0.000128	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—hematologic cancer	5.47e-05	0.000128	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.46e-05	0.000127	CcSEcCtD
Methyldopa—Paraesthesia—Doxorubicin—hematologic cancer	5.38e-05	0.000126	CcSEcCtD
Methyldopa—Vomiting—Prednisone—hematologic cancer	5.26e-05	0.000123	CcSEcCtD
Methyldopa—Rash—Prednisone—hematologic cancer	5.22e-05	0.000122	CcSEcCtD
Methyldopa—Dermatitis—Prednisone—hematologic cancer	5.22e-05	0.000122	CcSEcCtD
Methyldopa—Headache—Prednisone—hematologic cancer	5.19e-05	0.000121	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Doxorubicin—hematologic cancer	5.17e-05	0.000121	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—hematologic cancer	5.12e-05	0.00012	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—hematologic cancer	5.12e-05	0.00012	CcSEcCtD
Methyldopa—Hypersensitivity—Methotrexate—hematologic cancer	5.1e-05	0.000119	CcSEcCtD
Methyldopa—Asthenia—Methotrexate—hematologic cancer	4.97e-05	0.000116	CcSEcCtD
Methyldopa—Nausea—Prednisone—hematologic cancer	4.92e-05	0.000115	CcSEcCtD
Methyldopa—Hypersensitivity—Epirubicin—hematologic cancer	4.77e-05	0.000111	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—hematologic cancer	4.74e-05	0.000111	CcSEcCtD
Methyldopa—Diarrhoea—Methotrexate—hematologic cancer	4.73e-05	0.000111	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—hematologic cancer	4.65e-05	0.000109	CcSEcCtD
Methyldopa—Dizziness—Methotrexate—hematologic cancer	4.58e-05	0.000107	CcSEcCtD
Methyldopa—Diarrhoea—Epirubicin—hematologic cancer	4.43e-05	0.000103	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—hematologic cancer	4.41e-05	0.000103	CcSEcCtD
Methyldopa—Vomiting—Methotrexate—hematologic cancer	4.4e-05	0.000103	CcSEcCtD
Methyldopa—Rash—Methotrexate—hematologic cancer	4.36e-05	0.000102	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—hematologic cancer	4.36e-05	0.000102	CcSEcCtD
Methyldopa—Headache—Methotrexate—hematologic cancer	4.34e-05	0.000101	CcSEcCtD
Methyldopa—Asthenia—Doxorubicin—hematologic cancer	4.3e-05	0.0001	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—hematologic cancer	4.28e-05	0.0001	CcSEcCtD
Methyldopa—Vomiting—Epirubicin—hematologic cancer	4.12e-05	9.62e-05	CcSEcCtD
Methyldopa—Nausea—Methotrexate—hematologic cancer	4.11e-05	9.6e-05	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—hematologic cancer	4.1e-05	9.57e-05	CcSEcCtD
Methyldopa—Rash—Epirubicin—hematologic cancer	4.08e-05	9.54e-05	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—hematologic cancer	4.08e-05	9.53e-05	CcSEcCtD
Methyldopa—Headache—Epirubicin—hematologic cancer	4.06e-05	9.47e-05	CcSEcCtD
Methyldopa—Dizziness—Doxorubicin—hematologic cancer	3.96e-05	9.25e-05	CcSEcCtD
Methyldopa—Nausea—Epirubicin—hematologic cancer	3.85e-05	8.98e-05	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—hematologic cancer	3.81e-05	8.9e-05	CcSEcCtD
Methyldopa—Rash—Doxorubicin—hematologic cancer	3.78e-05	8.82e-05	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—hematologic cancer	3.77e-05	8.82e-05	CcSEcCtD
Methyldopa—Headache—Doxorubicin—hematologic cancer	3.75e-05	8.77e-05	CcSEcCtD
Methyldopa—Nausea—Doxorubicin—hematologic cancer	3.56e-05	8.31e-05	CcSEcCtD
Methyldopa—ADRA2A—Signaling by GPCR—PTHLH—hematologic cancer	3.18e-05	0.000272	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOR2—hematologic cancer	3.15e-05	0.000269	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	3.11e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PDGFB—hematologic cancer	3.1e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTGER4—hematologic cancer	3.09e-05	0.000265	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—hematologic cancer	3.08e-05	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL17—hematologic cancer	3.07e-05	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGRN—hematologic cancer	3.07e-05	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR5—hematologic cancer	3.02e-05	0.000258	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CDK2—hematologic cancer	3.01e-05	0.000258	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR4—hematologic cancer	3.01e-05	0.000257	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—IDH1—hematologic cancer	3e-05	0.000256	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEF1—hematologic cancer	2.96e-05	0.000253	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTO1—hematologic cancer	2.96e-05	0.000253	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TXN—hematologic cancer	2.96e-05	0.000253	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCC3—hematologic cancer	2.96e-05	0.000253	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	2.94e-05	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNA13—hematologic cancer	2.91e-05	0.000249	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL3—hematologic cancer	2.9e-05	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SPHK1—hematologic cancer	2.9e-05	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK14—hematologic cancer	2.89e-05	0.000247	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TIAM1—hematologic cancer	2.87e-05	0.000245	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CREBBP—hematologic cancer	2.85e-05	0.000244	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	2.85e-05	0.000244	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RASGRP1—hematologic cancer	2.81e-05	0.00024	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FN1—hematologic cancer	2.8e-05	0.00024	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—hematologic cancer	2.79e-05	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—UGT1A1—hematologic cancer	2.79e-05	0.000238	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAK3—hematologic cancer	2.78e-05	0.000238	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—hematologic cancer	2.73e-05	0.000234	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR4—hematologic cancer	2.73e-05	0.000234	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CRABP1—hematologic cancer	2.71e-05	0.000232	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC22A1—hematologic cancer	2.71e-05	0.000232	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—hematologic cancer	2.71e-05	0.000232	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—hematologic cancer	2.68e-05	0.000229	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—hematologic cancer	2.67e-05	0.000229	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL13—hematologic cancer	2.66e-05	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR7—hematologic cancer	2.66e-05	0.000228	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALOX5—hematologic cancer	2.64e-05	0.000226	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL3—hematologic cancer	2.64e-05	0.000225	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PTPN11—hematologic cancer	2.63e-05	0.000225	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCOR2—hematologic cancer	2.63e-05	0.000225	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL3RA—hematologic cancer	2.6e-05	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CRKL—hematologic cancer	2.6e-05	0.000222	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NUP98—hematologic cancer	2.56e-05	0.000219	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3R1—hematologic cancer	2.56e-05	0.000219	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RASGRP1—hematologic cancer	2.55e-05	0.000218	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CREBBP—hematologic cancer	2.53e-05	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GRB2—hematologic cancer	2.52e-05	0.000216	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RGS2—hematologic cancer	2.51e-05	0.000214	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CREBBP—hematologic cancer	2.48e-05	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADCY7—hematologic cancer	2.48e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOA3—hematologic cancer	2.48e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CMA1—hematologic cancer	2.48e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRH—hematologic cancer	2.48e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRIO—hematologic cancer	2.48e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NUP214—hematologic cancer	2.47e-05	0.000211	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	2.43e-05	0.000208	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGO2—hematologic cancer	2.42e-05	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPHK1—hematologic cancer	2.42e-05	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG2—hematologic cancer	2.42e-05	0.000207	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTR—hematologic cancer	2.42e-05	0.000207	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—hematologic cancer	2.4e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPAR1—hematologic cancer	2.4e-05	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC9—hematologic cancer	2.4e-05	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H3F3B—hematologic cancer	2.38e-05	0.000203	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—hematologic cancer	2.37e-05	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—hematologic cancer	2.37e-05	0.000203	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—hematologic cancer	2.36e-05	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—hematologic cancer	2.36e-05	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—hematologic cancer	2.33e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—hematologic cancer	2.3e-05	0.000196	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRB2—hematologic cancer	2.29e-05	0.000196	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3R1—hematologic cancer	2.27e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CSF2—hematologic cancer	2.26e-05	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SDC1—hematologic cancer	2.25e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3R1—hematologic cancer	2.22e-05	0.00019	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4B—hematologic cancer	2.21e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR2—hematologic cancer	2.21e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF19—hematologic cancer	2.19e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCG—hematologic cancer	2.18e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—JAK1—hematologic cancer	2.18e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAC2—hematologic cancer	2.17e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—JAK2—hematologic cancer	2.16e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DKK1—hematologic cancer	2.16e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT5B—hematologic cancer	2.14e-05	0.000183	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—hematologic cancer	2.09e-05	0.000179	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCY7—hematologic cancer	2.08e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—hematologic cancer	2.05e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CSF2—hematologic cancer	2.05e-05	0.000175	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—hematologic cancer	2.04e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2RA—hematologic cancer	2.03e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—XIAP—hematologic cancer	2.02e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	1.98e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—JAK1—hematologic cancer	1.98e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCG—hematologic cancer	1.98e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SH2B3—hematologic cancer	1.97e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMARCA4—hematologic cancer	1.97e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GZMB—hematologic cancer	1.96e-05	0.000167	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—hematologic cancer	1.94e-05	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNA1—hematologic cancer	1.91e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD44—hematologic cancer	1.91e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NQO1—hematologic cancer	1.91e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EIF4EBP1—hematologic cancer	1.9e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSPB1—hematologic cancer	1.9e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL3—hematologic cancer	1.9e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—hematologic cancer	1.89e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTHLH—hematologic cancer	1.88e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SDC1—hematologic cancer	1.88e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2RA—hematologic cancer	1.85e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTGER4—hematologic cancer	1.83e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LCK—hematologic cancer	1.82e-05	0.000156	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—hematologic cancer	1.81e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYCS—hematologic cancer	1.81e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSP90AA1—hematologic cancer	1.8e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H3F3A—hematologic cancer	1.78e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCZ—hematologic cancer	1.73e-05	0.000148	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—hematologic cancer	1.73e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—hematologic cancer	1.69e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—hematologic cancer	1.69e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PARP1—hematologic cancer	1.67e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FBXW7—hematologic cancer	1.65e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—hematologic cancer	1.65e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC2—hematologic cancer	1.61e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR4—hematologic cancer	1.61e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—hematologic cancer	1.6e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—hematologic cancer	1.59e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—hematologic cancer	1.58e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CBL—hematologic cancer	1.57e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL3—hematologic cancer	1.56e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—hematologic cancer	1.54e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN1—hematologic cancer	1.53e-05	0.000131	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MAPK3—hematologic cancer	1.52e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTPN11—hematologic cancer	1.51e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—hematologic cancer	1.51e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RASGRP1—hematologic cancer	1.51e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SYK—hematologic cancer	1.5e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSP90AA1—hematologic cancer	1.5e-05	0.000128	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—hematologic cancer	1.49e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—hematologic cancer	1.47e-05	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CREB1—hematologic cancer	1.46e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOR1—hematologic cancer	1.46e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—hematologic cancer	1.46e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT1—hematologic cancer	1.45e-05	0.000124	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—hematologic cancer	1.44e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—hematologic cancer	1.43e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6R—hematologic cancer	1.43e-05	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3R1—hematologic cancer	1.41e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—JAK2—hematologic cancer	1.37e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—hematologic cancer	1.36e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAP2K1—hematologic cancer	1.36e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRB2—hematologic cancer	1.35e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—hematologic cancer	1.35e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFA—hematologic cancer	1.35e-05	0.000116	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KITLG—hematologic cancer	1.33e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT5A—hematologic cancer	1.3e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—hematologic cancer	1.3e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—hematologic cancer	1.29e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN2B—hematologic cancer	1.29e-05	0.00011	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—hematologic cancer	1.28e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3R1—hematologic cancer	1.28e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—hematologic cancer	1.25e-05	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD86—hematologic cancer	1.25e-05	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—JAK2—hematologic cancer	1.24e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—hematologic cancer	1.23e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCOR1—hematologic cancer	1.22e-05	0.000105	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—hematologic cancer	1.21e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CSF2—hematologic cancer	1.21e-05	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF1—hematologic cancer	1.21e-05	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO1—hematologic cancer	1.19e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—hematologic cancer	1.19e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRB—hematologic cancer	1.19e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—hematologic cancer	1.18e-05	0.000101	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—hematologic cancer	1.17e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRA—hematologic cancer	1.17e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCG—hematologic cancer	1.17e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAK1—hematologic cancer	1.17e-05	9.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—hematologic cancer	1.16e-05	9.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2RA—hematologic cancer	1.09e-05	9.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—hematologic cancer	1.09e-05	9.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—hematologic cancer	1.08e-05	9.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—hematologic cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFB—hematologic cancer	1.05e-05	9e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—hematologic cancer	1.04e-05	8.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC2—hematologic cancer	1.03e-05	8.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—hematologic cancer	1.02e-05	8.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CREBBP—hematologic cancer	1.01e-05	8.62e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	9.9e-06	8.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	9.8e-06	8.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	9.61e-06	8.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—hematologic cancer	9.55e-06	8.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—hematologic cancer	9.49e-06	8.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—hematologic cancer	9.43e-06	8.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BAD—hematologic cancer	9.38e-06	8.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	9.38e-06	8.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	9.29e-06	7.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD80—hematologic cancer	9.1e-06	7.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	9.09e-06	7.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KIT—hematologic cancer	9.09e-06	7.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	9.09e-06	7.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3R1—hematologic cancer	9.02e-06	7.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	8.93e-06	7.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	8.7e-06	7.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	8.65e-06	7.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	8.54e-06	7.3e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	8.46e-06	7.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	8.44e-06	7.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	8.42e-06	7.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—hematologic cancer	8.33e-06	7.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	8.04e-06	6.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	7.99e-06	6.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	7.91e-06	6.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	7.82e-06	6.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	7.65e-06	6.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	7.54e-06	6.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	7.33e-06	6.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—hematologic cancer	7.19e-06	6.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	7.18e-06	6.14e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	7.16e-06	6.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	6.96e-06	5.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	6.96e-06	5.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—hematologic cancer	6.86e-06	5.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	6.65e-06	5.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	6.53e-06	5.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	6.46e-06	5.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	6.4e-06	5.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—hematologic cancer	6.39e-06	5.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	6.36e-06	5.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	6.23e-06	5.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUN—hematologic cancer	6.22e-06	5.32e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	6.03e-06	5.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	6.02e-06	5.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	5.89e-06	5.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	5.87e-06	5.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—hematologic cancer	5.74e-06	4.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—hematologic cancer	5.58e-06	4.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	5.43e-06	4.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	5.38e-06	4.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	5.37e-06	4.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	5.14e-06	4.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—hematologic cancer	5.08e-06	4.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—hematologic cancer	5e-06	4.28e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	4.99e-06	4.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	4.62e-06	3.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	4.24e-06	3.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—hematologic cancer	4.15e-06	3.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—hematologic cancer	4.11e-06	3.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	3.93e-06	3.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—hematologic cancer	3.76e-06	3.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	3.47e-06	2.97e-05	CbGpPWpGaD
